|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
|
TW321649B
(OSRAM)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
WO1996033977A1
(en)
*
|
1995-04-27 |
1996-10-31 |
Zeneca Limited |
Quinazoline derivatives
|
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
CA2242425C
(en)
|
1996-02-13 |
2006-07-18 |
Zeneca Limited |
Quinazoline derivatives as vegf inhibitors
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
|
DE69709319T2
(de)
|
1996-03-05 |
2002-08-14 |
Astrazeneca Ab, Soedertaelje |
4-anilinochinazolin derivate
|
|
ES2174250T5
(es)
|
1996-04-12 |
2010-04-21 |
Warner-Lambert Company Llc |
Inhibidores irreversibles de tirosina quinasas.
|
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
|
AU2912997A
(en)
*
|
1996-06-24 |
1998-01-14 |
Pfizer Inc. |
Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
|
EP0837063A1
(en)
*
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
|
US6002008A
(en)
*
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
|
US6090096A
(en)
|
1997-04-23 |
2000-07-18 |
Heartport, Inc. |
Antegrade cardioplegia catheter and method
|
|
DE19743435A1
(de)
|
1997-10-01 |
1999-04-08 |
Merck Patent Gmbh |
Benzamidinderivate
|
|
CN101219999A
(zh)
*
|
1998-04-29 |
2008-07-16 |
Osi药物公司 |
N-(乙炔苯基)-6,7-双(2-甲氧基乙氧基)-4-喹唑啉胺甲磺酸盐无水物和一水合物
|
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
|
US6384223B1
(en)
|
1998-07-30 |
2002-05-07 |
American Home Products Corporation |
Substituted quinazoline derivatives
|
|
HRP20010119B1
(hr)
|
1998-08-18 |
2008-05-31 |
The Regents Of The University Of California |
Sprječavanje stvaranja sluzi u dišnim putevima primjenom antagonista egf-r
|
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
RS49836B
(sr)
*
|
1999-03-31 |
2008-08-07 |
Pfizer Products Inc., |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
|
CA2375259C
(en)
|
1999-06-21 |
2009-04-28 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
|
JP2003504363A
(ja)
*
|
1999-07-09 |
2003-02-04 |
グラクソ グループ リミテッド |
プロテインチロシンキナーゼ阻害剤としてのアニリノキナゾリン類
|
|
GB9922173D0
(en)
|
1999-09-21 |
1999-11-17 |
Zeneca Ltd |
Chemical compounds
|
|
EP1218356A1
(en)
*
|
1999-09-21 |
2002-07-03 |
AstraZeneca AB |
Quinazoline compounds and pharmaceutical compositions containing them
|
|
GB9925958D0
(en)
*
|
1999-11-02 |
1999-12-29 |
Bundred Nigel J |
Therapeutic use
|
|
KR100881105B1
(ko)
|
1999-11-05 |
2009-02-02 |
아스트라제네카 아베 |
Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
|
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
|
UA74803C2
(uk)
*
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
|
DE60121931T2
(de)
|
2000-04-07 |
2007-03-01 |
Astrazeneca Ab |
Chinazolinverbindungen
|
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
|
EP1170011A1
(en)
*
|
2000-07-06 |
2002-01-09 |
Boehringer Ingelheim International GmbH |
Novel use of inhibitors of the epidermal growth factor receptor
|
|
AU2001278609B2
(en)
|
2000-08-21 |
2005-04-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
HU230302B1
(hu)
|
2000-10-20 |
2015-12-28 |
Eisai R&D Management Co., Ltd. |
Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
|
|
US7776315B2
(en)
|
2000-10-31 |
2010-08-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and additional active ingredients
|
|
EP1330444B1
(en)
|
2000-11-01 |
2011-03-23 |
Millennium Pharmaceuticals, Inc. |
Nitrogenous heterocyclic compounds and process for making them
|
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
|
LT3351246T
(lt)
|
2001-02-19 |
2019-07-10 |
Novartis Pharma Ag |
Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui
|
|
JP2002293773A
(ja)
*
|
2001-03-30 |
2002-10-09 |
Sumika Fine Chemicals Co Ltd |
キナゾリン誘導体の製造方法
|
|
RU2332415C2
(ru)
*
|
2001-04-27 |
2008-08-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Производные пиразола, полезные в качестве ингибиторов протеинкиназы
|
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
|
EP1408980A4
(en)
|
2001-06-21 |
2004-10-20 |
Ariad Pharma Inc |
NEW QUINAZOLINES AND THEIR USE
|
|
CA2478050A1
(en)
|
2002-03-01 |
2003-09-12 |
Pfizer Inc. |
Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7078409B2
(en)
|
2002-03-28 |
2006-07-18 |
Beta Pharma, Inc. |
Fused quinazoline derivatives useful as tyrosine kinase inhibitors
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
DE10221018A1
(de)
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
|
ES2316758T3
(es)
|
2002-05-16 |
2009-04-16 |
Novartis Ag |
Uso de aglutinantes del receptor edg en el cancer.
|
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
|
WO2004008099A2
(en)
|
2002-07-15 |
2004-01-22 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
|
|
EP2298805A3
(en)
|
2002-09-27 |
2011-04-13 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
WO2004046101A2
(en)
|
2002-11-20 |
2004-06-03 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
|
|
US7488823B2
(en)
|
2003-11-10 |
2009-02-10 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
|
JPWO2004060400A1
(ja)
*
|
2003-01-06 |
2006-05-11 |
那波 宏之 |
上皮成長因子受容体を分子標的とする抗精神病薬
|
|
GB0302882D0
(en)
*
|
2003-02-07 |
2003-03-12 |
Univ Cardiff |
Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
|
|
US7148231B2
(en)
*
|
2003-02-17 |
2006-12-12 |
Hoffmann-La Roche Inc. |
[6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
|
|
US7223749B2
(en)
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
PA8595001A1
(es)
|
2003-03-04 |
2004-09-28 |
Pfizer Prod Inc |
Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
|
|
ATE508747T1
(de)
|
2003-03-10 |
2011-05-15 |
Eisai R&D Man Co Ltd |
C-kit kinase-hemmer
|
|
WO2004092144A2
(en)
*
|
2003-04-16 |
2004-10-28 |
F. Hoffmann-La Roche Ag |
Quinazoline compounds useful as p38 kinase inhibitors
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
|
PE20050158A1
(es)
|
2003-05-19 |
2005-05-12 |
Irm Llc |
Compuestos inmunosupresores y composiciones
|
|
EP1633870B1
(en)
|
2003-05-30 |
2013-03-27 |
OncoTherapy Science, Inc. |
Process for screening a drug response in cancer patients
|
|
CA2528961A1
(en)
|
2003-06-09 |
2005-01-06 |
Samuel Waksal |
Methods of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
|
|
BRPI0411126A
(pt)
|
2003-06-10 |
2006-07-18 |
Hoffmann La Roche |
derivados de 1,3,4-triaza-fenaleno e 1,3,4,6-tetraazafenaleno
|
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
|
CN1984660B
(zh)
|
2003-07-03 |
2010-12-15 |
美瑞德生物工程公司 |
作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
|
|
WO2006074147A2
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
|
JP4828421B2
(ja)
*
|
2003-08-14 |
2011-11-30 |
アレイ バイオファーマ、インコーポレイテッド |
受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
|
|
WO2005016347A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Pfizer Products Inc. |
Dosing schedule for erbb2 anticancer agents
|
|
MXPA06002296A
(es)
|
2003-08-29 |
2006-05-22 |
Pfizer |
Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
|
|
ATE395346T1
(de)
|
2003-09-16 |
2008-05-15 |
Astrazeneca Ab |
Chinazolinderivate als tyrosinkinaseinhibitoren
|
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
DE10349113A1
(de)
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
|
CN100450998C
(zh)
|
2003-11-11 |
2009-01-14 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
GEP20084572B
(en)
|
2003-12-23 |
2008-12-25 |
Pfizer |
Novel quinoline derivatives
|
|
ES2315834T3
(es)
|
2004-02-03 |
2009-04-01 |
Astrazeneca Ab |
Derivados de quinazolina.
|
|
EP1720841B1
(en)
|
2004-02-19 |
2015-11-04 |
Rexahn Pharmaceuticals, Inc. |
Quinazoline derivatives and therapeutic use thereof
|
|
PL1735348T3
(pl)
|
2004-03-19 |
2012-11-30 |
Imclone Llc |
Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu
|
|
EP1733056B1
(en)
|
2004-03-31 |
2013-05-22 |
The General Hospital Corporation |
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
|
|
RS52545B
(sr)
|
2004-04-07 |
2013-04-30 |
Novartis Ag |
Inhibitori protein apoptoze (iap)
|
|
WO2005107747A2
(en)
|
2004-05-06 |
2005-11-17 |
Bioresponse, Llc |
Diindolymethane formulations for the treatment of leiomyomas
|
|
BRPI0510883B8
(pt)
|
2004-06-01 |
2021-05-25 |
Genentech Inc |
composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
|
|
JP2008504292A
(ja)
|
2004-06-24 |
2008-02-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド |
免疫増強用の化合物
|
|
JP2008505174A
(ja)
|
2004-07-15 |
2008-02-21 |
ゼンコー・インコーポレイテッド |
最適化Ｆｃ変異体
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
EP1797881B1
(en)
|
2004-09-17 |
2009-04-15 |
Eisai R&D Management Co., Ltd. |
Medicinal composition with improved stability and reduced gelation properties
|
|
CN101065151B
(zh)
|
2004-09-23 |
2014-12-10 |
健泰科生物技术公司 |
半胱氨酸改造的抗体和偶联物
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
EP2325206B1
(en)
|
2004-11-12 |
2014-03-19 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
|
US7947676B2
(en)
|
2004-12-14 |
2011-05-24 |
Astrazeneca Ab |
Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
US7989486B2
(en)
|
2004-12-30 |
2011-08-02 |
Bioresponse, L.L.C. |
Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions
|
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
|
US7625911B2
(en)
|
2005-01-12 |
2009-12-01 |
Mai De Ltd. |
Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
|
|
TWI441646B
(zh)
|
2005-01-21 |
2014-06-21 |
Genentech Inc |
帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
|
|
KR101345002B1
(ko)
|
2005-01-21 |
2013-12-31 |
아스텍스 테라퓨틱스 리미티드 |
제약 화합물
|
|
GB0501999D0
(en)
*
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
DK1854789T3
(da)
*
|
2005-02-23 |
2013-10-21 |
Shionogi & Co |
Quinazolinderivat med tyrosin-kinase inhibitorisk aktivitet
|
|
CA2596133C
(en)
|
2005-02-23 |
2016-11-15 |
Genentech, Inc. |
Extending time to disease progression or survival in cancer patients
|
|
UY29398A1
(es)
|
2005-02-26 |
2006-10-02 |
Astrazeneca Ab |
Derivados de quinazolinas, sussales farmacéuticamente aceptables, composiciones que los contienen, procedimientos de preparación y aplicacións.
|
|
SI1859793T1
(sl)
|
2005-02-28 |
2011-08-31 |
Eisai R&D Man Co Ltd |
Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
|
|
EP1871345B1
(en)
*
|
2005-04-12 |
2012-08-01 |
Elan Pharma International Limited |
Nanoparticulate erlotinib formulations
|
|
CN1854130B
(zh)
*
|
2005-04-15 |
2011-04-20 |
中国医学科学院药物研究所 |
喹唑啉衍生物、及其制法和药物组合物与用途
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
CA2680945C
(en)
|
2005-06-17 |
2014-03-18 |
Imclone Systems Incorporated |
Anti-pdgfralpha antibodies
|
|
CA2652434A1
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Optimized proteins that target ep-cam
|
|
EP2281901B1
(en)
|
2005-08-02 |
2013-11-27 |
Eisai R&D Management Co., Ltd. |
Anti-tumour pharmaceutical composition with angiogenesis inhibitors
|
|
WO2007025044A2
(en)
|
2005-08-24 |
2007-03-01 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
|
DE602006018331D1
(de)
|
2005-09-20 |
2010-12-30 |
Astrazeneca Ab |
4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
|
|
DK1931709T3
(en)
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
|
CN101316590B
(zh)
|
2005-11-07 |
2011-08-03 |
卫材R&D管理有限公司 |
血管生成抑制剂和c-kit激酶抑制剂的组合使用
|
|
CA2833852C
(en)
|
2005-11-11 |
2014-10-21 |
Boehringer Ingelheim International Gmbh |
Quinazoline derivatives for the treatment of cancer diseases
|
|
US9006224B2
(en)
|
2005-11-21 |
2015-04-14 |
Novartis Ag |
Neuroendocrine tumor treatment
|
|
WO2007060691A2
(en)
*
|
2005-11-23 |
2007-05-31 |
Natco Pharma Limited |
A novel process for the preparation of erlotinib
|
|
BRPI0619424B1
(pt)
*
|
2005-12-05 |
2022-02-08 |
Pfizer Products Inc |
Uso de inibidores c-met/hgfrs para a fabricação de medicamentos
|
|
CN101003514A
(zh)
|
2006-01-20 |
2007-07-25 |
上海艾力斯医药科技有限公司 |
喹唑啉衍生物、其制备方法及用途
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
CN101484587B
(zh)
|
2006-02-03 |
2014-02-12 |
英克隆有限责任公司 |
Igf-ir拮抗剂作为辅药用于前列腺癌的治疗
|
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
|
EP2606890A1
(en)
|
2006-04-05 |
2013-06-26 |
Novartis AG |
Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
|
|
EP2591775A1
(en)
|
2006-04-05 |
2013-05-15 |
Novartis AG |
Combinations comprising mtor inhibitors for treating cancer
|
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
|
WO2007124288A1
(en)
|
2006-04-19 |
2007-11-01 |
Novartis Ag |
Indazole compounds and methods for inhibition of cdc7
|
|
WO2007128820A1
(en)
|
2006-05-09 |
2007-11-15 |
Novartis Ag |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
|
EP2036557B1
(en)
|
2006-05-18 |
2015-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
|
WO2007138612A2
(en)
*
|
2006-05-25 |
2007-12-06 |
Vittal Mallya Scientific Research Foundation |
A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4- yl]-(3-ethynylphenyl)amine hydrochloride
|
|
WO2007138613A2
(en)
*
|
2006-05-25 |
2007-12-06 |
Vittal Mallya Scientific Research Foundation |
A process for synthesis of [6,7-bis-(2-methoxyethoxy)-quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride
|
|
WO2008012105A1
(en)
*
|
2006-07-28 |
2008-01-31 |
Synthon B.V. |
Crystalline erlotinib
|
|
RS53263B
(sr)
|
2006-08-14 |
2014-08-29 |
Xencor Inc. |
Optimizovana antitela usmerena na cd19
|
|
CN101511793B
(zh)
|
2006-08-28 |
2011-08-03 |
卫材R&D管理有限公司 |
针对未分化型胃癌的抗肿瘤剂
|
|
US20100008910A1
(en)
|
2006-09-12 |
2010-01-14 |
John Chant |
Methods and compositions for the diagnosis and treatment of cancer
|
|
US8877764B2
(en)
|
2006-09-18 |
2014-11-04 |
Boehringer Ingelheim International Gmbh |
Method for treating cancer harboring EGFR mutations
|
|
KR20090073121A
(ko)
|
2006-09-29 |
2009-07-02 |
노파르티스 아게 |
Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
|
|
MX2009003673A
(es)
|
2006-10-04 |
2009-04-22 |
Pfizer Prod Inc |
Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio.
|
|
EP2073803B1
(en)
|
2006-10-12 |
2018-09-19 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
US8883790B2
(en)
|
2006-10-12 |
2014-11-11 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
US8372856B2
(en)
|
2006-10-27 |
2013-02-12 |
Synthon Bv |
Hydrates of erlotinib hydrochloride
|
|
WO2008057253A2
(en)
|
2006-10-27 |
2008-05-15 |
Bioresponse, L.L.C. |
Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
US8343950B2
(en)
*
|
2006-12-15 |
2013-01-01 |
Concert Pharmaceuticals, Inc. |
Quinazoline derivatives and methods of treatment
|
|
US20100048503A1
(en)
|
2007-01-19 |
2010-02-25 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of pancreatic cancer
|
|
AU2008211952B2
(en)
|
2007-01-29 |
2012-07-19 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
|
EA200901041A1
(ru)
|
2007-02-06 |
2010-02-26 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
|
CN101245050A
(zh)
|
2007-02-14 |
2008-08-20 |
上海艾力斯医药科技有限公司 |
4-苯胺喹唑啉衍生物的盐
|
|
EP2491923A3
(en)
|
2007-02-15 |
2012-12-26 |
Novartis AG |
Combinations of therapeutic agents for treating cancer
|
|
US8349855B2
(en)
|
2007-02-21 |
2013-01-08 |
Natco Pharma Limited |
Polymorphs of erlotinib hydrochloride and method of preparation
|
|
PL2132573T3
(pl)
|
2007-03-02 |
2014-09-30 |
Genentech Inc |
Prognozowanie odpowiedzi na inhibitor dimeryzacji HER oparte na niskiej ekspresji HER3
|
|
JP5524041B2
(ja)
*
|
2007-04-04 |
2014-06-18 |
シプラ・リミテッド |
エルロチニブおよびその薬学的に許容可能な塩の製造方法
|
|
LT2176298T
(lt)
|
2007-05-30 |
2018-04-10 |
Xencor, Inc. |
Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
|
|
EP2171090B1
(en)
|
2007-06-08 |
2013-04-03 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
|
SG183036A1
(en)
|
2007-07-17 |
2012-08-30 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
WO2009030224A2
(de)
*
|
2007-09-07 |
2009-03-12 |
Schebo Biotech Ag |
Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
|
|
EA018716B1
(ru)
|
2007-10-29 |
2013-10-30 |
Натко Фарма Лимитед |
Новые 4-(тетразол-5-ил) хиназолиновые производные в качестве противораковых средств
|
|
JP5638244B2
(ja)
|
2007-11-09 |
2014-12-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質と抗腫瘍性白金錯体との併用
|
|
UY31478A1
(es)
|
2007-11-21 |
2009-07-17 |
|
Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
|
|
WO2009080694A1
(en)
|
2007-12-20 |
2009-07-02 |
Novartis Ag |
Thiazole derivatives used as pi 3 kinase inhibitors
|
|
KR101616758B1
(ko)
|
2007-12-26 |
2016-04-29 |
젠코어 인코포레이티드 |
ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
|
|
AU2008347940A1
(en)
|
2008-01-18 |
2009-07-23 |
Natco Pharma Limited |
6,7-dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
PL2245026T3
(pl)
|
2008-02-07 |
2013-01-31 |
Boehringer Ingelheim Int |
Spirocykliczne heterocykle, leki zawierające te związki, ich zastosowanie i sposób ich produkcji
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
KR101673621B1
(ko)
|
2008-03-24 |
2016-11-07 |
노파르티스 아게 |
아릴술폰아미드-계 매트릭스 메탈로프로테아제 억제제
|
|
CN101544609A
(zh)
|
2008-03-25 |
2009-09-30 |
上海艾力斯医药科技有限公司 |
4-苯胺喹唑啉衍生物的结晶形式
|
|
CN102036955B
(zh)
|
2008-03-26 |
2013-03-27 |
诺瓦提斯公司 |
脱乙酰酶b的异羟肟酸盐为基础的抑制剂
|
|
CN102083801A
(zh)
*
|
2008-03-28 |
2011-06-01 |
康瑟特制药公司 |
喹唑啉衍生物和治疗方法
|
|
ES2444128T3
(es)
|
2008-05-13 |
2014-02-24 |
Astrazeneca Ab |
Nueva SAL-554
|
|
CA2723984A1
(en)
|
2008-05-14 |
2009-11-19 |
Genomic Health Inc. |
Predictors of patient response to treatment with egf receptor inhibitors
|
|
CN101584696A
(zh)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
包含喹唑啉衍生物的组合物及制备方法、用途
|
|
DE102008031039A1
(de)
|
2008-06-30 |
2009-12-31 |
Dömling, Alexander, Priv.-Doz. Dr. |
Tarceva zur Anwendung in der Organtransplantation.
|
|
JP5539351B2
(ja)
|
2008-08-08 |
2014-07-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
|
|
EP2344161B1
(en)
|
2008-10-16 |
2018-12-19 |
Celator Pharmaceuticals, Inc. |
Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
|
|
MX2011004824A
(es)
|
2008-11-07 |
2012-01-12 |
Triact Therapeutics Inc |
Uso de derivados de butano catecólico en terapia contra el cáncer.
|
|
US8334293B2
(en)
|
2008-11-11 |
2012-12-18 |
Eli Lilly And Company |
P70 S6 kinase inhibitor and EGFR inhibitor combination therapy
|
|
CN103204794A
(zh)
|
2008-12-18 |
2013-07-17 |
诺瓦提斯公司 |
新的盐
|
|
KR20170062554A
(ko)
|
2008-12-18 |
2017-06-07 |
노파르티스 아게 |
1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
|
|
RU2011129230A
(ru)
|
2008-12-18 |
2013-01-27 |
Новартис Аг |
Новая полиморфная форма 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил]азетидин-3-карбоновой кислоты
|
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
|
TW201031406A
(en)
|
2009-01-29 |
2010-09-01 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
|
EP2213281A1
(en)
|
2009-02-02 |
2010-08-04 |
Ratiopharm GmbH |
Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
|
JP2012518657A
(ja)
|
2009-02-25 |
2012-08-16 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
併用抗癌治療
|
|
WO2010099137A2
(en)
|
2009-02-26 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the emt status of tumor cells in vivo
|
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
JP2012520893A
(ja)
|
2009-03-18 |
2012-09-10 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
Ｅｇｆｒ阻害薬及びｉｇｆ−１ｒ阻害剤の投与を含む組み合わせ癌治療
|
|
WO2010109443A1
(en)
|
2009-03-26 |
2010-09-30 |
Ranbaxy Laboratories Limited |
Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
|
|
WO2010149755A1
(en)
|
2009-06-26 |
2010-12-29 |
Novartis Ag |
1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
|
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
|
EP2451445B1
(en)
|
2009-07-06 |
2019-04-03 |
Boehringer Ingelheim International GmbH |
Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
|
|
US9050341B2
(en)
*
|
2009-07-14 |
2015-06-09 |
Natco Pharma Limited |
Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
|
CN102573846B
(zh)
|
2009-08-17 |
2015-10-07 |
因特利凯公司 |
杂环化合物及其用途
|
|
MX2012002179A
(es)
|
2009-08-20 |
2012-03-16 |
Novartis Ag |
Compuestos heterociclicos de oxima.
|
|
CA2771936A1
(en)
|
2009-08-26 |
2011-03-03 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
EP2494070A2
(en)
|
2009-10-30 |
2012-09-05 |
Bristol-Myers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
|
PE20121471A1
(es)
|
2009-11-04 |
2012-11-01 |
Novartis Ag |
Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
|
|
JP2013510564A
(ja)
|
2009-11-13 |
2013-03-28 |
パンガエア ビオテック、ソシエダッド、リミターダ |
肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
|
|
CN102770456B
(zh)
|
2009-12-04 |
2018-04-06 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体、抗体类似物、组合物和方法
|
|
GEP20135998B
(en)
|
2009-12-08 |
2013-12-25 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
|
AU2012265844A1
(en)
|
2009-12-08 |
2013-05-02 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
EP2348020A1
(en)
|
2009-12-23 |
2011-07-27 |
Esteve Química, S.A. |
Preparation process of erlotinib
|
|
CN102712640A
(zh)
|
2010-01-12 |
2012-10-03 |
弗·哈夫曼-拉罗切有限公司 |
三环杂环化合物、其组合物和应用方法
|
|
EP2542692B1
(en)
|
2010-03-04 |
2016-08-24 |
Carpén, Olli |
Method for selecting patients for treatment with an egfr inhibitor
|
|
CN102869359A
(zh)
|
2010-03-17 |
2013-01-09 |
弗·哈夫曼-拉罗切有限公司 |
咪唑并吡啶和嘌呤化合物、组合物和使用方法
|
|
JP2013523098A
(ja)
|
2010-03-29 |
2013-06-17 |
ザイムワークス，インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
|
JP2013528787A
(ja)
|
2010-04-16 |
2013-07-11 |
ジェネンテック， インコーポレイテッド |
Ｐｉ３ｋ／ａｋｔキナーゼ経路インヒビターの効果の予測バイオマーカーとしてのｆｏｘ０３ａ
|
|
DE202010006543U1
(de)
|
2010-05-07 |
2010-09-09 |
Ratiopharm Gmbh |
Erlotinibresinat
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
WO2011144059A1
(zh)
|
2010-05-21 |
2011-11-24 |
深圳信立泰药业股份有限公司 |
一种稠环喹唑啉类衍生物及其应用
|
|
WO2011147102A1
(zh)
*
|
2010-05-28 |
2011-12-01 |
翔真生物科技股份有限公司 |
6,7-取代基-4-苯胺类喹唑啉的合成方法
|
|
MX2012014776A
(es)
|
2010-06-25 |
2013-01-29 |
Eisai R&D Man Co Ltd |
Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
NZ628796A
(en)
*
|
2010-07-23 |
2016-02-26 |
Generics Uk Ltd |
Pure erlotinib
|
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
|
BR112013006016A2
(pt)
|
2010-09-15 |
2016-06-07 |
Hoffmann La Roche |
compostos de azabenzotiazol, composições e métodos de uso
|
|
WO2012035078A1
(en)
|
2010-09-16 |
2012-03-22 |
Novartis Ag |
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
|
IT1402029B1
(it)
|
2010-10-14 |
2013-08-28 |
Italiana Sint Spa |
Procedimento per la preparazione di erlotinib
|
|
US9309322B2
(en)
|
2010-11-12 |
2016-04-12 |
Scott & White Healthcare (Swh) |
Antibodies to tumor endothelial marker 8
|
|
WO2012066061A1
(en)
|
2010-11-19 |
2012-05-24 |
F. Hoffmann-La Roche Ag |
Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
|
|
CN103476770B
(zh)
|
2010-11-25 |
2017-02-15 |
拉蒂欧制药有限责任公司 |
阿法替尼盐和多晶型物
|
|
DE102010053124A1
(de)
|
2010-12-01 |
2012-06-06 |
Volkswagen Ag |
Kupplung, insbesondere für ein Getriebe eines Kraftfahrzeuges, vorzugsweise Doppelkupplung für ein automatisches oder automatisiertes Doppelkupplungsgetriebe
|
|
JP2014500308A
(ja)
|
2010-12-21 |
2014-01-09 |
ノバルティス アーゲー |
Ｖｐｓ３４阻害剤としてのビヘテロアリール化合物
|
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
|
PT2670753T
(pt)
|
2011-01-31 |
2017-01-10 |
Novartis Ag |
Novos derivados heterocíclicos
|
|
US20130324526A1
(en)
|
2011-02-10 |
2013-12-05 |
Novartis Ag |
[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
|
KR20210043016A
(ko)
|
2011-03-04 |
2021-04-20 |
뉴젠 세러퓨틱스 인코포레이티드 |
알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
|
|
EP2683740B1
(en)
|
2011-03-10 |
2018-07-04 |
Omeros Corporation |
Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
|
MX2013009931A
(es)
|
2011-04-18 |
2013-10-01 |
Eisai R&D Man Co Ltd |
Agentes terapeuticos contra tumores.
|
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
|
AU2012249421B9
(en)
|
2011-04-28 |
2015-10-22 |
Novartis Ag |
17alpha-hydroxylase/C17,20-lyase inhibitors
|
|
CN102918029B
(zh)
*
|
2011-05-17 |
2015-06-17 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
WO2012175520A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
|
WO2012175487A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
|
CN102267952B
(zh)
*
|
2011-06-21 |
2013-12-11 |
天津市汉康医药生物技术有限公司 |
喹唑啉类化合物、其制备方法和用途
|
|
AU2012277391A1
(en)
|
2011-06-27 |
2013-12-19 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
|
US8575339B2
(en)
*
|
2011-07-05 |
2013-11-05 |
Xueheng Cheng |
Derivatives of erlotinib
|
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
|
HK1199255A1
(en)
|
2011-08-12 |
2015-06-26 |
F. Hoffmann-La Roche Ag |
Indazole compounds, compositions and methods of use
|
|
US9102724B2
(en)
|
2011-08-12 |
2015-08-11 |
Omeros Corporation |
Anti-FZD10 monoclonal antibodies and methods for their use
|
|
AU2012389562A1
(en)
|
2011-08-17 |
2014-07-24 |
Dennis Brown |
Compositions and methods to improve the therapeutic benefit of subotimally administered chemical compounds including substituted hexitols such as dibromodulcitol
|
|
WO2013033380A1
(en)
|
2011-08-31 |
2013-03-07 |
Genentech, Inc. |
Diagnostic markers
|
|
EP2755976B1
(en)
|
2011-09-15 |
2018-07-18 |
Novartis AG |
6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
|
|
HK1198365A1
(en)
|
2011-09-20 |
2015-04-10 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
|
JP2014531213A
(ja)
|
2011-09-30 |
2014-11-27 |
ジェネンテック， インコーポレイテッド |
上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるｅｇｆｒキナーゼ阻害薬に対する応答
|
|
HU230483B1
(hu)
|
2011-10-10 |
2016-07-28 |
Egis Gyógyszergyár Nyrt. |
Erlotinib sók
|
|
US20140309229A1
(en)
|
2011-10-13 |
2014-10-16 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
|
PT2771342T
(pt)
|
2011-10-28 |
2016-08-17 |
Novartis Ag |
Derivados de purina e o seu uso no tratamento de doença
|
|
CN104080787B
(zh)
|
2011-11-29 |
2016-09-14 |
诺华股份有限公司 |
吡唑并吡咯烷化合物
|
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
|
DK2794600T3
(en)
|
2011-12-22 |
2018-03-12 |
Novartis Ag |
-2,3-Dihydro-benzo [1,4] oxazine derivatives and related compounds such as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of rheumatoid arthritis
|
|
CN104125953A
(zh)
|
2011-12-23 |
2014-10-29 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
|
KR20140107578A
(ko)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
|
|
US9126980B2
(en)
|
2011-12-23 |
2015-09-08 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
AU2012355623A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
AU2012355619A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
JO3357B1
(ar)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
مركبات إيميدازوبيروليدينون
|
|
CN104379602B
(zh)
|
2012-03-08 |
2017-05-03 |
哈洛齐梅公司 |
具有条件活性的抗表皮生长因子受体抗体及其使用方法
|
|
MX2014011500A
(es)
|
2012-03-27 |
2014-12-05 |
Genentech Inc |
Diagnosticos y tratamientos relacionados a inhibidores her3.
|
|
ES2894830T3
(es)
|
2012-04-03 |
2022-02-16 |
Novartis Ag |
Productos combinados con inhibidores de tirosina·cinasa y su uso
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
JP6381523B2
(ja)
|
2012-05-16 |
2018-08-29 |
ノバルティス アーゲー |
Ｐｉ−３キナーゼ阻害剤の投与レジメン
|
|
CN104321325B
(zh)
|
2012-05-24 |
2016-11-16 |
诺华股份有限公司 |
吡咯并吡咯烷酮化合物
|
|
CN104582732A
(zh)
|
2012-06-15 |
2015-04-29 |
布里格姆及妇女医院股份有限公司 |
治疗癌症的组合物及其制造方法
|
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
|
NZ630289A
(en)
|
2012-09-04 |
2016-08-26 |
Shilpa Medicare Ltd |
Crystalline erlotinib hydrochloride process
|
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫－吡啶并－□衍生物之固體形式
|
|
US9334239B2
(en)
|
2012-12-21 |
2016-05-10 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
|
US9403827B2
(en)
|
2013-01-22 |
2016-08-02 |
Novartis Ag |
Substituted purinone compounds
|
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
|
WO2014118112A1
(en)
|
2013-01-29 |
2014-08-07 |
Synthon B.V. |
Pharmaceutical composition comprising erlotinib hydrochloride
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
US9834575B2
(en)
|
2013-02-26 |
2017-12-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
US10035801B2
(en)
|
2013-03-13 |
2018-07-31 |
Genentech, Inc. |
Pyrazolo compounds and uses thereof
|
|
CN105246482A
(zh)
|
2013-03-15 |
2016-01-13 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
|
WO2014147246A1
(en)
|
2013-03-21 |
2014-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
|
US10517861B2
(en)
|
2013-05-14 |
2019-12-31 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
KR20160049003A
(ko)
|
2013-09-05 |
2016-05-04 |
제넨테크, 인크. |
항증식성 화합물
|
|
EP3044593A4
(en)
|
2013-09-09 |
2017-05-17 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
HK1226081A1
(zh)
|
2013-09-12 |
2017-09-22 |
Halozyme, Inc. |
修饰的抗表皮生长因子受体抗体及其使用方法
|
|
SG11201510740YA
(en)
|
2013-09-17 |
2016-01-28 |
Obi Pharma Inc |
Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
|
|
CA2920059A1
(en)
|
2013-09-22 |
2015-03-26 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
|
AR097894A1
(es)
|
2013-10-03 |
2016-04-20 |
Hoffmann La Roche |
Inhibidores terapéuticos de cdk8 o uso de los mismos
|
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
|
|
CA2930359C
(en)
|
2013-12-06 |
2022-03-01 |
Novartis Ag |
Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
|
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
|
MY189089A
(en)
|
2013-12-17 |
2022-01-25 |
Genentech Inc |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
|
JP6517319B2
(ja)
|
2014-03-28 |
2019-05-22 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ |
置換されたヘテロアリール化合物および使用方法
|
|
AU2015241037B2
(en)
|
2014-03-31 |
2020-10-15 |
Genentech, Inc. |
Anti-OX40 antibodies and methods of use
|
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
|
KR20160132496A
(ko)
|
2014-04-03 |
2016-11-18 |
인빅터스 온콜로지 피비티. 엘티디. |
초분자 조합 치료제
|
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
KR20170036037A
(ko)
|
2014-07-31 |
2017-03-31 |
노파르티스 아게 |
조합 요법
|
|
CN106660964B
(zh)
|
2014-08-28 |
2021-09-03 |
卫材R&D管理有限公司 |
高纯度喹啉衍生物及其生产方法
|
|
JP6814730B2
(ja)
|
2014-09-05 |
2021-01-20 |
ジェネンテック， インコーポレイテッド |
治療用化合物およびその使用
|
|
JP2017529358A
(ja)
|
2014-09-19 |
2017-10-05 |
ジェネンテック， インコーポレイテッド |
がんの処置のためのｃｂｐ／ｅｐ３００阻害剤およびｂｅｔ阻害剤の使用
|
|
CN107912040B
(zh)
|
2014-10-10 |
2021-04-06 |
基因泰克公司 |
作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
|
|
JP2017536347A
(ja)
|
2014-10-17 |
2017-12-07 |
ノバルティス アーゲー |
セリチニブとｅｇｆｒ阻害剤の組合せ
|
|
CA2908441A1
(en)
|
2014-10-28 |
2016-04-28 |
Cerbios-Pharma Sa |
Process for the preparation of erlotinib
|
|
SG11201703448QA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
RU2017119231A
(ru)
|
2014-11-03 |
2018-12-06 |
Дженентек, Инк. |
Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
|
|
WO2016073282A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
WO2016077375A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
SG10201807625PA
(en)
|
2014-11-17 |
2018-10-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
WO2016086200A1
(en)
|
2014-11-27 |
2016-06-02 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
|
WO2016082879A1
(en)
*
|
2014-11-27 |
2016-06-02 |
Synthon B.V. |
Pharmaceutical composition comprising erlotinib hydrochloride
|
|
EP3237639A2
(en)
|
2014-12-23 |
2017-11-01 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
|
CA2969830A1
(en)
|
2014-12-24 |
2016-06-30 |
Genentech, Inc. |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
|
WO2016109546A2
(en)
|
2014-12-30 |
2016-07-07 |
Genentech, Inc. |
Methods and compositions for prognosis and treatment of cancers
|
|
EP3242874B1
(en)
|
2015-01-09 |
2018-10-31 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
|
WO2016112284A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
(piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
|
|
EP3242875B1
(en)
|
2015-01-09 |
2022-02-23 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
|
CN107531692B
(zh)
|
2015-01-29 |
2020-12-25 |
基因泰克公司 |
治疗化合物及其用途
|
|
EP3250552B1
(en)
|
2015-01-30 |
2019-03-27 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
PL3263106T3
(pl)
|
2015-02-25 |
2024-04-02 |
Eisai R&D Management Co., Ltd. |
Sposób tłumienia goryczy pochodnej chinoliny
|
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
CN104725327B
(zh)
*
|
2015-03-03 |
2017-08-25 |
山东大学 |
一种盐酸厄洛替尼的环保制备方法
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
EP3280736A1
(en)
|
2015-04-07 |
2018-02-14 |
F. Hoffmann-La Roche AG |
Antigen binding complex having agonistic activity and methods of use
|
|
MX2017014381A
(es)
|
2015-05-12 |
2018-03-02 |
Genentech Inc |
Metodos terapeuticos y diagnosticos para cancer.
|
|
JP7144935B2
(ja)
|
2015-05-29 |
2022-09-30 |
ジェネンテック， インコーポレイテッド |
癌のための治療方法及び診断方法
|
|
KR20180025888A
(ko)
|
2015-06-08 |
2018-03-09 |
제넨테크, 인크. |
항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
|
|
EP3303399A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies
|
|
ES2886107T3
(es)
|
2015-06-16 |
2021-12-16 |
Prism Biolab Co Ltd |
Antineoplásico
|
|
CN116327953A
(zh)
|
2015-06-17 |
2023-06-27 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
|
CN105017162B
(zh)
*
|
2015-06-26 |
2017-10-27 |
陕西师范大学 |
4‑对丙烯基苯氨基喹唑啉衍生物及其在制备抗肿瘤药物中的应用
|
|
AU2016309356B2
(en)
|
2015-08-20 |
2021-06-24 |
Eisai R&D Management Co., Ltd. |
Tumor therapeutic agent
|
|
AU2016313263B2
(en)
|
2015-08-26 |
2021-02-04 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Condensed tricyclic compounds as protein kinase inhibitors
|
|
US20180243304A1
(en)
|
2015-08-28 |
2018-08-30 |
Novartis Ag |
Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
|
|
EP3344806A4
(en)
|
2015-09-04 |
2019-03-20 |
OBI Pharma, Inc. |
GLYCAN NETWORKS AND METHODS OF USE
|
|
US9938257B2
(en)
|
2015-09-11 |
2018-04-10 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
MY186016A
(en)
|
2015-09-25 |
2021-06-14 |
Genentech Inc |
Anti-tigit antibodies and methods of use
|
|
RU2018119085A
(ru)
|
2015-11-02 |
2019-12-04 |
Новартис Аг |
Схема введения ингибитора фосфатидилинозитол-3-киназы
|
|
EP3389662B1
(en)
|
2015-12-16 |
2021-12-01 |
Genentech, Inc. |
Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
|
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
KR102500659B1
(ko)
|
2016-02-29 |
2023-02-16 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
US11041017B2
(en)
|
2016-03-29 |
2021-06-22 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
WO2017180581A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
JP2019515670A
(ja)
|
2016-04-15 |
2019-06-13 |
ジェネンテック， インコーポレイテッド |
がんをモニタリングし治療するための方法
|
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
|
IL262296B2
(en)
|
2016-04-22 |
2024-09-01 |
Obi Pharma Inc |
Cancer immunotherapy by immune activation or immune modulation via globo series antigens
|
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
|
MA45122A
(fr)
|
2016-05-24 |
2019-04-10 |
Constellation Pharmaceuticals Inc |
Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
|
|
MA45146A
(fr)
|
2016-05-24 |
2021-03-24 |
Constellation Pharmaceuticals Inc |
Dérivés de pyrazolopyridine pour le traitement du cancer
|
|
PT3468997T
(pt)
|
2016-06-08 |
2023-12-07 |
Debra Zack |
Tratamento de doenças relacionadas com igg4 com anticorpos anti-cd19 com ligação cruzada a cd32b
|
|
CN109312407A
(zh)
|
2016-06-08 |
2019-02-05 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
CN110072545A
(zh)
|
2016-07-27 |
2019-07-30 |
台湾浩鼎生技股份有限公司 |
免疫原性/治疗性聚糖组合物及其用途
|
|
JP7121724B2
(ja)
|
2016-07-29 |
2022-08-18 |
オービーアイ ファーマ，インコーポレイテッド |
ヒト抗体、医薬組成物及び方法
|
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
|
JP7579056B2
(ja)
|
2016-10-06 |
2024-11-07 |
ジェネンテック， インコーポレイテッド |
がんのための治療方法及び診断方法
|
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
|
WO2018081648A2
(en)
|
2016-10-29 |
2018-05-03 |
Genentech, Inc. |
Anti-mic antibidies and methods of use
|
|
AU2017361549B2
(en)
|
2016-11-21 |
2023-12-21 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
|
MY196830A
(en)
|
2016-12-22 |
2023-05-03 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
|
MX380144B
(es)
|
2017-02-08 |
2025-03-12 |
Eisai R&D Man Co Ltd |
Composicion farmaceutica de tratamiento de tumores.
|
|
EP3589754B1
(en)
|
2017-03-01 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
CN106928069B
(zh)
*
|
2017-03-21 |
2019-03-19 |
上海玉函化工有限公司 |
一种4,5-二(2-甲氧基乙氧基)-2-硝基苯甲酸乙酯的制备方法
|
|
JP2020516638A
(ja)
|
2017-04-13 |
2020-06-11 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを処置する方法における使用のための、インターロイキン２イムノコンジュゲート、ｃｄ４０アゴニスト、および任意選択のｐｄ−１軸結合アンタゴニスト
|
|
CA3061888A1
(en)
|
2017-05-16 |
2018-11-22 |
Eisai R&D Management Co., Ltd. |
Treatment of hepatocellular carcinoma
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
CN107200715B
(zh)
*
|
2017-06-22 |
2020-05-29 |
陕西师范大学 |
喹唑啉衍生物及其在制备抗肿瘤药物中的应用
|
|
AU2018304458B2
(en)
|
2017-07-21 |
2021-12-09 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
AU2018316343B2
(en)
|
2017-08-11 |
2025-06-12 |
Genentech, Inc. |
Anti-CD8 antibodies and uses thereof
|
|
EP3679159A1
(en)
|
2017-09-08 |
2020-07-15 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
|
EP4403175A3
(en)
|
2017-09-08 |
2024-10-02 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
|
US20200290978A1
(en)
*
|
2017-09-26 |
2020-09-17 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
WO2019084395A1
(en)
|
2017-10-27 |
2019-05-02 |
University Of Virginia Patent Foundation |
COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
|
|
JP7544597B2
(ja)
|
2017-11-06 |
2024-09-03 |
ジェネンテック， インコーポレイテッド |
がんの診断及び療法
|
|
WO2019099311A1
(en)
|
2017-11-19 |
2019-05-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
EP3740756A4
(en)
|
2018-01-15 |
2021-10-27 |
Epiaxis Therapeutics Pty Ltd |
AGENTS AND METHODS FOR PREDICTING THE THERAPEUTIC RESPONSE
|
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
CN117624045A
(zh)
|
2018-01-26 |
2024-03-01 |
埃克塞里艾克西斯公司 |
用于治疗激酶依赖性病症的化合物
|
|
CR20250117A
(es)
|
2018-01-26 |
2025-05-09 |
Exelixis Inc |
COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355)
|
|
WO2019148043A1
(en)
|
2018-01-26 |
2019-08-01 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
|
TWI660728B
(zh)
*
|
2018-02-09 |
2019-06-01 |
國立交通大學 |
胺基喹唑啉衍生物及其醫藥組合物與用途
|
|
AU2019225249A1
(en)
|
2018-02-26 |
2020-09-17 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
|
|
CA3098574A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
ES2995514T3
(en)
|
2018-05-04 |
2025-02-10 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
|
ES2986917T3
(es)
|
2018-05-10 |
2024-11-13 |
Amgen Inc |
Inhibidores de KRAS G12C para el tratamiento del cáncer
|
|
US20210363590A1
(en)
|
2018-05-21 |
2021-11-25 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
|
EP3802535B1
(en)
|
2018-06-01 |
2022-12-14 |
Amgen, Inc |
Kras g12c inhibitors and methods of using the same
|
|
MA52780A
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
|
AU2019336588B2
(en)
|
2018-06-12 |
2022-07-28 |
Amgen Inc. |
KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
|
SG11202012446UA
(en)
|
2018-06-23 |
2021-01-28 |
Genentech Inc |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
TWI853822B
(zh)
|
2018-06-27 |
2024-09-01 |
台灣浩鼎生技股份有限公司 |
用於糖蛋白工程的糖苷合成酶變體及其使用方法
|
|
CN110642796B
(zh)
*
|
2018-06-27 |
2023-03-17 |
烟台药物研究所 |
一种喹唑啉类衍生物及其应用
|
|
EP3823611A1
(en)
|
2018-07-18 |
2021-05-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
|
CN112805267B
(zh)
|
2018-09-03 |
2024-03-08 |
豪夫迈·罗氏有限公司 |
用作tead调节剂的甲酰胺和磺酰胺衍生物
|
|
KR20210063330A
(ko)
|
2018-09-19 |
2021-06-01 |
제넨테크, 인크. |
방광암에 대한 치료 및 진단 방법
|
|
AU2019342133B8
(en)
|
2018-09-21 |
2025-08-07 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
|
KR20210137422A
(ko)
|
2018-09-25 |
2021-11-17 |
블랙 다이아몬드 테라퓨틱스, 인코포레이티드 |
티로신 키나아제 억제제로서의 퀴나졸린 유도체, 조성물, 이들의 제조 방법 및 이들의 용도
|
|
CN113194954A
(zh)
|
2018-10-04 |
2021-07-30 |
国家医疗保健研究所 |
用于治疗角皮病的egfr抑制剂
|
|
EP3867405A4
(en)
|
2018-10-17 |
2022-07-20 |
The University of Queensland |
Epigenetic biomarker and uses therefor
|
|
KR20210079311A
(ko)
|
2018-10-18 |
2021-06-29 |
제넨테크, 인크. |
육종성 신장암에 대한 진단과 치료 방법
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
JP7454572B2
(ja)
|
2018-11-19 |
2024-03-22 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
|
|
AU2019403488B2
(en)
|
2018-12-20 |
2025-07-24 |
Amgen Inc. |
KIF18A inhibitors
|
|
US12441705B2
(en)
|
2018-12-20 |
2025-10-14 |
Amgen Inc. |
KIF18A inhibitors
|
|
EA202191730A1
(ru)
|
2018-12-20 |
2021-08-24 |
Эмджен Инк. |
Ингибиторы kif18a
|
|
MX2021007157A
(es)
|
2018-12-20 |
2021-08-16 |
Amgen Inc |
Heteroarilamidas utiles como inhibidores de kif18a.
|
|
CN113195000A
(zh)
|
2018-12-21 |
2021-07-30 |
第一三共株式会社 |
抗体-药物缀合物和激酶抑制剂的组合
|
|
WO2020163589A1
(en)
|
2019-02-08 |
2020-08-13 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
CN113710706A
(zh)
|
2019-02-27 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
|
|
US20220146495A1
(en)
|
2019-02-27 |
2022-05-12 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
|
MX2021010319A
(es)
|
2019-03-01 |
2021-12-10 |
Revolution Medicines Inc |
Compuestos biciclicos de heteroarilo y usos de estos.
|
|
KR20210146288A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로사이클릴 화합물 및 이의 용도
|
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
|
WO2020226986A2
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
NZ782284A
(en)
|
2019-05-21 |
2024-11-29 |
Amgen Inc |
Solid state forms
|
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
JP7771047B2
(ja)
|
2019-08-02 |
2025-11-17 |
アムジエン・インコーポレーテツド |
Ｋｉｆ１８ａ阻害剤
|
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
|
WO2021026099A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
AU2020324963A1
(en)
|
2019-08-02 |
2022-02-24 |
Amgen Inc. |
KIF18A inhibitors
|
|
CN119390683A
(zh)
|
2019-08-15 |
2025-02-07 |
黑钻治疗公司 |
炔基喹唑啉化合物
|
|
KR20220057563A
(ko)
|
2019-09-04 |
2022-05-09 |
제넨테크, 인크. |
Cd8 결합제 및 이의 용도
|
|
JP2022551422A
(ja)
|
2019-09-26 |
2022-12-09 |
エグゼリクシス， インコーポレイテッド |
ピリドン化合物およびタンパク質キナーゼの調節における使用の方法
|
|
MX2022003610A
(es)
|
2019-09-27 |
2022-04-20 |
Genentech Inc |
Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
|
AU2020369569A1
(en)
|
2019-10-24 |
2022-04-14 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
|
|
WO2021083949A1
(en)
|
2019-10-29 |
2021-05-06 |
F. Hoffmann-La Roche Ag |
Bifunctional compounds for the treatment of cancer
|
|
US11566007B2
(en)
|
2019-11-04 |
2023-01-31 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US11608346B2
(en)
|
2019-11-04 |
2023-03-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
EP4054720A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
KR20220092580A
(ko)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
혈액암의 치료를 위한 진단과 치료 방법
|
|
EP4620531A3
(en)
|
2019-11-08 |
2025-11-26 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
|
WO2021094379A1
(en)
|
2019-11-12 |
2021-05-20 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
CN114728905B
(zh)
|
2019-11-13 |
2025-08-01 |
基因泰克公司 |
治疗性化合物及使用方法
|
|
BR112022009390A2
(pt)
|
2019-11-14 |
2022-08-09 |
Amgen Inc |
Síntese melhorada de composto inibidor de kras g12c
|
|
CA3161156A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
|
JP2023505100A
(ja)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
共有ｒａｓ阻害剤及びその使用
|
|
AR120741A1
(es)
|
2019-12-13 |
2022-03-16 |
Genentech Inc |
Anticuerpos anti-ly6g6d y métodos de uso
|
|
EP4076667A1
(en)
|
2019-12-20 |
2022-10-26 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
WO2021142026A1
(en)
|
2020-01-07 |
2021-07-15 |
Revolution Medicines, Inc. |
Shp2 inhibitor dosing and methods of treating cancer
|
|
AU2021211871A1
(en)
|
2020-01-20 |
2022-09-08 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
AU2021212662A1
(en)
|
2020-01-27 |
2022-08-11 |
F. Hoffmann-La Roche Ag |
Methods for treatment of cancer with an anti-TIGIT antagonist antibody
|
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
WO2021257503A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
|
BR112022025801A2
(pt)
|
2020-06-18 |
2023-10-03 |
Hoffmann La Roche |
Métodos para tratar um paciente e para tratar um paciente com escc avançado, kit, anticorpo, uso de um anticorpo e uso de um antagonista de ligação
|
|
TW202214253A
(zh)
|
2020-06-18 |
2022-04-16 |
美商銳新醫藥公司 |
延遲、預防及治療對ｒａｓ抑制劑之後天抗性之方法
|
|
JP7741831B2
(ja)
|
2020-06-30 |
2025-09-18 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
|
|
CN115997123A
(zh)
|
2020-06-30 |
2023-04-21 |
国家医疗保健研究所 |
用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
WO2022031749A1
(en)
|
2020-08-03 |
2022-02-10 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
KR20230078657A
(ko)
|
2020-08-27 |
2023-06-02 |
에노시 테라퓨틱스 코퍼레이션 |
자가면역 질환 및 암을 치료하기 위한 방법 및 조성물
|
|
IL301062A
(en)
|
2020-09-03 |
2023-05-01 |
Revolution Medicines Inc |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
CR20230165A
(es)
|
2020-09-15 |
2023-06-02 |
Revolution Medicines Inc |
Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
|
|
IL301524A
(en)
|
2020-09-23 |
2023-05-01 |
Erasca Inc |
Tricyclic pyridones and pyrimidones
|
|
WO2022076462A1
(en)
|
2020-10-05 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
AR124449A1
(es)
|
2020-12-22 |
2023-03-29 |
Qilu Regor Therapeutics Inc |
Inhibidores de sos1 y usos de los mismos
|
|
US20240368150A1
(en)
|
2021-02-12 |
2024-11-07 |
Hoffmann-La Roche Inc. |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
|
JP2024507794A
(ja)
|
2021-02-19 |
2024-02-21 |
エグゼリクシス， インコーポレイテッド |
ピリドン化合物および使用方法
|
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
|
CN118561952A
(zh)
|
2021-05-05 |
2024-08-30 |
锐新医药公司 |
Ras抑制剂
|
|
CR20230558A
(es)
|
2021-05-05 |
2024-01-24 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cáncer
|
|
EP4347603A1
(en)
|
2021-05-25 |
2024-04-10 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
CA3226019A1
(en)
|
2021-07-20 |
2023-01-26 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their preparation, and uses
|
|
EP4384522A1
(en)
|
2021-08-10 |
2024-06-19 |
Erasca, Inc. |
Selective kras inhibitors
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
WO2023097194A2
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
JP2024541508A
(ja)
|
2021-11-24 |
2024-11-08 |
ジェネンテック， インコーポレイテッド |
治療用インダゾール化合物およびがんの治療における使用方法
|
|
EP4448526A1
(en)
|
2021-12-17 |
2024-10-23 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
WO2023144127A1
(en)
|
2022-01-31 |
2023-08-03 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
WO2023172858A1
(en)
|
2022-03-07 |
2023-09-14 |
Amgen Inc. |
A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
CA3255389A1
(en)
|
2022-03-31 |
2023-10-05 |
Astrazeneca Ab |
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Combination with an AKT Inhibitor for the Treatment of Cancer
|
|
AU2022450448A1
(en)
|
2022-04-01 |
2024-10-10 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AU2023284422A1
(en)
|
2022-06-07 |
2024-12-19 |
Genentech, Inc. |
Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
|
|
EP4536364A1
(en)
|
2022-06-10 |
2025-04-16 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
MA71241A
(fr)
|
2022-06-27 |
2025-04-30 |
Astrazeneca Ab |
Combinaisons impliquant des inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour traiter le cancer
|
|
AU2023305619A1
(en)
|
2022-07-13 |
2025-01-23 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
EP4558524A1
(en)
|
2022-07-19 |
2025-05-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CN119677732A
(zh)
|
2022-08-11 |
2025-03-21 |
豪夫迈·罗氏有限公司 |
双环四氢氮杂䓬衍生物
|
|
CA3262845A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES
|
|
CR20250042A
(es)
|
2022-08-11 |
2025-03-25 |
Hoffmann La Roche |
Derivados de tetrahidrotiazepina bicíclicos
|
|
EP4568746A1
(en)
|
2022-08-11 |
2025-06-18 |
F. Hoffmann-La Roche AG |
Bicyclic tetrahydrothiazepine derivatives
|
|
JP2025536257A
(ja)
|
2022-10-14 |
2025-11-05 |
ブラック ダイアモンド セラピューティクス，インコーポレイティド |
イソキノリンまたは６－ａｚａ－キノリン誘導体を使用してがんを治療する方法
|
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
|
EP4608424A1
(en)
|
2022-10-24 |
2025-09-03 |
AGS Therapeutics SAS |
Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
|
|
EP4609201A1
(en)
|
2022-10-25 |
2025-09-03 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
|
EP4665735A1
(en)
|
2023-02-17 |
2025-12-24 |
Erasca, Inc. |
Kras inhibitors
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
AU2024252105A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
KR20250172857A
(ko)
|
2023-04-14 |
2025-12-09 |
레볼루션 메디슨즈, 인크. |
Ras 억제제의 결정형
|
|
WO2024229406A1
(en)
|
2023-05-04 |
2024-11-07 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
WO2024233341A1
(en)
|
2023-05-05 |
2024-11-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024254455A1
(en)
|
2023-06-08 |
2024-12-12 |
Genentech, Inc. |
Macrophage signatures for diagnostic and therapeutic methods for lymphoma
|
|
WO2025024257A1
(en)
|
2023-07-21 |
2025-01-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2025034702A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Rmc-6291 for use in the treatment of ras protein-related disease or disorder
|
|
TW202515614A
(zh)
|
2023-08-25 |
2025-04-16 |
美商建南德克公司 |
治療非小細胞肺癌之方法及組成物
|
|
TW202530228A
(zh)
|
2023-10-12 |
2025-08-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025176843A1
(en)
|
2024-02-21 |
2025-08-28 |
Ags Therapeutics Sas |
Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|